CYTK Cytokinetics, Incorporated
Price Chart
Executive Summary
Cytokinetics presented new data at ESC Heart Failure 2026 reinforcing the clinical profile of MYQORZO (aficamten) in obstructive HCM, including superiority over metoprolol in MAPLE-HCM, long-term safety in FOREST-HCM, and favorable left atrial remodeling in SEQUOIA-HCM. The press release is a routine scientific update with no new regulatory or financial catalysts, and the stock impact is likely muted given the absence of material commercial or regulatory news.
Actionable Insight
This is a routine scientific update with no new regulatory or commercial catalysts. Monitor for upcoming full results from ACACIA-HCM (nHCM) and potential FDA discussions, which could be more material. No immediate trading action warranted.
Key Facts
- MAPLE-HCM showed aficamten significantly improved exercise capacity, outflow gradients, and NT-proBNP across all doses, while metoprolol showed no improvement.
- FOREST-HCM open-label extension data (up to 96 weeks) showed no increase in arrhythmias, including NSVT or atrial fibrillation, with aficamten.
- SEQUOIA-HCM analysis showed aficamten significantly improved left atrial reservoir strain (+2.9%; p=0.004) and conduit strain (+2.2%; p=0.001) vs placebo.
- Real-world evidence from 273 patients showed 26.6% activity impairment due to oHCM, with higher impairment in obstructive vs non-obstructive HCM (30.2% vs 19.2%; p=0.0003).
- MYQORZO is already approved in the U.S., EU, and China for symptomatic oHCM; no new regulatory actions were announced.
Financial Impact
No financial figures disclosed; data reinforces existing clinical profile without changing revenue or guidance.
Risk Factors
- Competition from other cardiac myosin inhibitors (e.g., mavacamten) could limit market share.
- Potential safety concerns from boxed warning on heart failure risk may constrain adoption.
- Regulatory setbacks in expanding indications (nHCM, pediatric) could disappoint expectations.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292055 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 20, 2026
3d ago
|
Insider Cluster
| — | awaiting T+5 | — | — |
|
May 11, 2026
12d ago
|
Press Release
| $74.56 $75.18 | ▲ +0.83% | ▲ +0.92% | $76.94 (+3.19%) |
|
May 8, 2026
15d ago
|
Press Release
| $76.91 $78.64 | ▼ −2.25% | ▼ −0.79% | $76.94 (−0.04%) |
|
May 7, 2026
16d ago
|
Press Release
| $74.29 $77.22 | ▼ −3.94% | ▼ −2.44% | $76.94 (−3.57%) |
|
May 5, 2026
18d ago
|
424B5
| $74.84 $74.81 | ▼ −0.04% | ▼ −1.17% | $76.94 (+2.81%) |
|
May 5, 2026
18d ago
|
8-K
| $74.84 $74.81 | ▼ −0.04% | ▼ −1.17% | $76.94 (+2.81%) |
|
May 5, 2026
18d ago
|
Press Release
| $77.09 $74.81 | ▼ −2.96% | ▼ −4.94% | $76.94 (−0.19%) |
|
May 5, 2026
19d ago
|
Insider Cluster
| $77.09 $74.56 | ▼ −3.28% | ▼ −5.27% | $76.94 (−0.19%) |
|
May 5, 2026
19d ago
|
Insider Cluster
| $74.84 $74.81 | ▼ −0.04% | ▼ −1.17% | $76.94 (+2.81%) |
|
May 4, 2026
19d ago
|
Press Release
| $77.09 $74.56 | ▼ −3.28% | ▼ −5.27% | $76.94 (−0.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access